Skip to main content

Table 4 Factors associated with increased risk of VTE in patients with NSCLC

From: Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer

Patients Group

SHR

95% CI

P-value

Tumor histology (%)

 Non-adenocarcinoma

1

  

 Adenocarcinoma

2.40

1.11–5.19

0.027

ECOG PS

 0–1

1

  

 2–3

1.91

1.18–3.09

0.008

EGFR gene

 Mutated

1

  

 Wild

1.81

1.07–3.07

0.028

Age

  ≥ 60

1

  

  < 60

1.27

0.79–2.02

0.324

Sex

 Female

1

  

 Male

1.03

0.63–1.66

0.920

Tumor Stage

 Distant metastasis

1

  

 Localized

1.18

0.67–2.07

0.569

KRAS gene

 Wild

1

  

 Mutated

1.10

0.52–2.32

0.814

  1. Abbreviations: CI confidence interval, ECOG Eastern Cooperative Oncology Group, SHR Sub-distribution hazard ratio, NSCLC non-small cell lung cancer, PS performance status, VTE venous thromboembolism
  2. *The variables were entered into the Fine-Gray regression model and included age, gender, ECOG PS (0–1 vs. 2–3), EGFR (mutated vs. wild), KRAS (mutated vs. wild), tumor histology (adenocarcinoma vs. nonadenocarcinoma), and tumor stage (localized stage vs. distant metastasis). All variables were shown in the table
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us